UPDATE: Morgan Stanley Removes PT on Express Scripts on Management Meeting Takeaways

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on

, but removed the $70.00 price target. In the report, Morgan Stanley noted, “2013/2014 selling season in line with expectations, with EBIT retention ahead of revenue retention rate. Looking ahead to 2014/2015 FEP mail and retail contract is marquee account up for renewal ESRX will be focusing on (CVS incumbent). Management expects the DOD will communicate its renewal decision (ESRX incumbent) in February, inline with our expectations.” Express Scripts Holding Company closed on Friday at $66.62.